Gilead pays $65mm cash to buy EpiTherapeutics
Gilead Sciences Inc. paid $65mm cash to acquire privately held epigenetics company EpiTherapeutics APS.
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.